

# Transparency: Working with Patient Groups - Theory into practice

Paul Woods



# Industry support for increased transparency

- **Necessary for company and industry reputation**
  - Leaders get positive publicity
- **Responding to critical commentaries on our activities**
  - Let's base the debate on facts
- **Compliance with code and regulatory requirements**
  - now and in the future



# Working with patient groups - Roche

http://www.roche.com/corporate\_responsibility/patients/patient-groups.htm

Global Web Site [Roche Worldwide](#) [Deutsch](#) [Site Map](#) [Contact](#) + Text Size -



[Home](#) [About Roche](#) [Products](#) **[Corporate Responsibility](#)** [Research & Development](#) [Media](#) [Investors](#) [Careers](#)

Search for...

[Corporate Responsibility](#) > [Patients](#) > **[Patient Groups](#)**

## Working with patient groups



Roche is proud of its history of working with patient groups. The company wishes to ensure that collaborations reflect common values of integrity, maintenance of independence, respect, equity, transparency and mutual benefit. These values act as guiding principles for the guidelines.

Patient groups are increasingly important partners for Roche. We share an interest in helping patients understand and manage their disease, including having timely and equitable access to the treatment they need. Roche is able to contribute a range of skills, expertise and knowledge which might enhance the patient organisation's activities.

Patient groups are important in helping Roche to gain a greater understanding of what it is like to live with a disease, the challenges facing patients and their families and the role that drug therapies play in the management of the disease. They also provide the company with an insight on how to support healthcare professionals who in turn support patients.

Roche has established a set of guidelines which should underlie the relationship between Roche and any patient group. Any agency working with patient groups on behalf of Roche must also follow these guidelines.

Through implementing these guidelines, Roche will move to a role as a true partner working in collaboration with the patient group, where the patient group knows explicitly what it can expect from Roche.

In 2008 Roche provided support to > [a range of patient group organisations](#), globally.


[Print](#) [Bookmark](#) [delicious.us](#) [digg](#)

### Related Links

- > [List of Sponsored Patient Groups](#)
- > [Products](#)
- > [Stakeholder Dialogue](#)
- > [Sustainability Principles](#)

### Downloads

- [Working with Patient Groups: Good Practice Guidelines](#)
- [Working with Patient Groups Positions](#)
- [Corporate Principles](#)



# Working with patient groups - Roche

http://www.roche.com/corporate\_responsibility/patients/patient-groups/patient-groups-list.htm

Global Web Site | Roche Worldwide | Deutsch | Site Map | Contact | + Text Size -

Home | About Roche | Products | **Corporate Responsibility** | Research & Development | Media | Investors | Careers

Search for...

Corporate Responsibility > Patients > Patient Groups > **Sponsored Patient Groups**

## Sponsored Patient Groups

In 2008 Roche provided support to a range of patient group organisations, globally:

Select country:  Select division:

Country	Division	Recipient	Activity
Argentina	Pharma	A.P.A.T. (Assistance to transplanted patients)	Collaboration to provide patient support (campaigns, world kidney day, disease awareness, bioequivalence comparisons, patient conferences)
Argentina	Pharma	A.R.S.I. (R.A patients)	Administration, educational material, patient supportive activities
Argentina	Pharma	ACIAPO (Association of Integral Assistance for Oncology Patients)	Breast cancer awareness campaigns, free mammography
Argentina	Pharma	Adolescentes x la Vida (Teens for Life)	Integral adherence support to new/on Fuzeon patients
Argentina	Pharma	Apostar a la Vida (Bet for Life)	Educational grants
Argentina	Pharma	APPANER (PRO Partnership help for parents of CF Children)	Support to adherence & education for CF patients and their families
Argentina	Pharma	Fundación Pacientes de Cáncer de Pulmón. (Lung Cancer Patients' Foundation)	Community Awareness Activities during November
Argentina	Pharma	Fundación Principios (Principle Foundation)	Collaboration to stimulate disease awareness (chronic kidney disease) for patients and their relatives
Argentina	Pharma	Fundación Sostén (Support Foundation)	Awareness activities
Argentina	Pharma	HUESPED Foundation	Institution dedicated to inform and educate about AIDS, helping the inquirer, doctors and patients
Argentina	Pharma	IBIS Foundation for Research on HIV / AIDS	Support to ARV treatment adherence
Argentina	Pharma	Linfomas Argentina (Lymphomas Argentina)	Collaboration to run awareness campaigns to NHL patients and patient relatives
Argentina	Pharma	MACMA (Breast Cancer Patients Movement)	Educational grants
Australia	Pharma	All About Acne	Core support for education about acne; Support to produce All About Acne DVD for schools program
Australia	Pharma	Arthritis Australia	Part-industry sponsorship for 'Parliamentary Friends of Arthritis' launch; educational booklet for consumers; and website upgrade



# Working with patient groups - Roche



## Roche Position on Working with Patient Groups

### Interactions with Patient Groups – Integrity and Transparency

Pharmaceutical companies are increasingly partnering with patient groups on projects ranging from disease awareness campaigns to clinical trial design and implementation. Different stakeholders, e.g. governments, the public and the media, are calling for integrity and transparency in terms of how the industry interacts with these groups, including the provision of financial and in-kind support. Roche understands and fully supports the request for integrity and the need for public transparency and consistently high standards of conduct in any interaction with patient groups.

### Values added by Patient Groups

Patient groups provide patients with support and information on how to live with their disease or condition, represent patient views and campaign for change on issues that affect patients' lives. Some carry out vital research into the causes and potential treatments for specific conditions. Patient groups play also a crucial role by safeguarding the rights of patients. Patient groups offer Roche valuable insights that influence our work around the world and across therapeutic areas – from drug development through regulatory approval and reimbursement into product launch and marketing.

### Roche's Vision and Position

Roche's commitment to patients is demonstrated in many ways throughout the Roche Group and is fundamental to what we believe to be Roche's most significant contribution to society: to create, produce and market innovative solutions of high quality for unmet medical needs. Hence, Roche and patient groups share a common vision to improve patient's access to innovative treatments and services. Roche is convinced that an open dialogue and transparent exchange of information among all the stakeholders in the healthcare community is vital to advancing access and healthcare delivery to patients. Building and sustaining relationships with patient groups is an efficient way for Roche to come up to its patient commitment and its commitment and responsibility to society as a whole.

Roche works with a wide range of patient groups in a variety of different disease areas, such as oncology, virology, inflammatory diseases, metabolic diseases and diseases of the central nervous system as well as in the area of diagnostics technologies. Our idea of innovation in healthcare centers on patient needs and benefits. Best placed to identify patients' needs are the patients themselves supported by their doctors, families or carers. Therefore, patient groups are important partners for Roche. Interacting with patient groups enables Roche to learn about unmet patient needs; such valuable information will guide us in the development of new medicines. Our aim is to support the voice of patients and to foster a constructive

1



## Roche Working with patient groups: Good practice guidelines



# Working with patient groups – GSK

Address <http://www.gsk.com/responsibility/transparency.htm>

Home  
About us  
Our mission and strategy  
Our products  
Your health  
Responsibility  
Our work with communities  
Research & development  
Investors  
Media centre  
Careers

2008 REPORT

## Our responsibility

gsk GlaxoSmithKline

**Responsibility**

- Public policy and patient advocacy
- Transparency

**Transparency**

We believe that being transparent about our support for patient groups helps build trust with our stakeholders, including the groups themselves.

We publish information on all our work with patient groups in our Europe and Asia Pacific, Japan and Emerging Markets regions, as well as information on our support for patient groups working globally, including details of the funding received. See details of our funding for patient organisations.

We were the first pharmaceutical company to publish this level of information and it goes beyond industry codes of practice that at most require a list of the groups funded.

Detailed information for GSK Australia and Canada can be found on their websites.

In the US, from February 2009 we will report educational and charitable grants provided to health-related organisations, including hospitals, teaching institutions and patient advocacy groups. The report will be updated quarterly.

See details of our funding for patient organisations

**Working with patient groups**

Our Standard Operating Procedures state that:

- Any involvement with a patient organisation must be declared and transparent
- GSK must neither seek patient organisation endorsement for its medicines, nor pay patient groups to endorse GSK services
- Medicines must not be promoted to patient organisations
- GSK must not create patient organisations, must not be the sole funding sponsor of a patient organisation, and should not provide more than 25 per cent funding to patient organisations. Exceptions may be allowed in the case of rare disease focus or start-up funding up to 50 per cent. However, must be agreed with directly with the local country or region general manager or head of regional government affairs
- GSK must not seek a direct return on investment from the funding of a patient organisation

**Quick links**

Research Access  
Environment  
Ethical conduct Global health

Print page  
Add to My Report  
Go to My Report

**Patient group funding**

- Details of relationships with patient groups
- Working with patient groups

## Working with patient groups

Our Standard Operating Procedures state that:

- Any involvement with a patient organisation must be declared and transparent
- GSK must neither seek patient organisation endorsement for its medicines, nor pay patient groups to endorse GSK services
- Medicines must not be promoted to patient organisations
- GSK must not create patient organisations, must not be the sole funding sponsor of a patient organisation, and should not provide more than 25 per cent funding to patient organisations. Exceptions may be allowed in the case of rare disease focus or start-up funding up to 50 per cent. However, must be agreed with directly with the local country or region general manager or head of regional government affairs
- GSK must not seek a direct return on investment from the funding of a patient organisation
- Any information on GSK pipeline compounds must be factual and non-promotional and provided to patient organisations as part of a scientific dialogue
- It is acceptable for GSK clinical trials or medical personnel to work with patient organisations to ensure optimal clinical trial recruitment, and to consult them on clinical trial design and protocols
- GSK must not directly sponsor patient organisation representatives to attend medical congresses, conferences and other healthcare professional events. Exceptions include where the representative is invited to speak at the conference or where the medical congress has a specific workstream designed for patients; GSK may sponsor representatives to attend non-medical congresses
- GSK may pay a modest honorarium or speaker fee to the patient organisation that an advisory board member or speaker represents
- Any third party working for GSK on a given project must be fully transparent about this relationship when interacting with a patient group on the project



# Working with patient groups – GSK

Address <http://www.gsk.com/responsibility/patient-group-funding.htm>

Home  
About us  
Our mission and strategy  
Our products  
Your health  
Responsibility  
Our work with communities  
Research & development  
Investors  
Media centre  
Careers

2008 REPORT

## Our responsibility

gsk GlaxoSmithKline

Home » Responsibility » Public policy and patient advocacy » **Patient group funding**

### Responsibility

- Public policy and patient advocacy
  - Our approach to external affairs
  - Public policy activity in 2008
  - Political contributions and lobbying expenditures
  - Patient advocacy
  - Patient group funding
    - UK groups
    - PAN European groups
    - National European groups
    - International groups
    - US groups
  - Q&As

### Patient group funding

Patient groups provide people with support and information on how to live with their disease, represent patient views and campaign for change on issues that affect patients' and carers lives. Some also carry out vital research into the causes and potential treatments for specific conditions.

We work with a wide range of patient groups in a variety of different disease areas, such as cancer, asthma, diabetes and multiple sclerosis. Our interest in patient advocacy is about understanding patient needs and their illness. Our aim is to support the voice of patients and to foster a constructive healthcare debate for all stakeholders'. GSK and patient groups share a vision to improve patient's access to effective treatments and services.

We are committed to working with patient groups at the highest levels of transparency and ethical standards. Key principles of our work with patient groups are trust and mutual respect. We enter into relationships committed to sustaining a long-term working relationship, which also reinforces the credibility and independence of patient groups.

#### Global principles for working with patient groups

- The independence of patient groups, of their political judgement and of their activities shall be assured.
- In all co-operative matters, transparency is vital.
- Any joint policies undertaken between patient groups and GSK shall be based on mutual respect and trust.
- We shall refrain from using undue influence to promote specific medicines or services.
- In any working with patient groups we will always comply with local laws/governance.

Quick links

Research Access  
Ethical conduct Global health

**In the community**  
What we do  
Find out more about our work in the community.

Address <http://www.gsk.com/responsibility/patient-groups/european-patient-organisations.htm>

Home  
About us  
Our mission and strategy  
Our products  
Your health  
Responsibility  
Our work with communities  
Research & development  
Investors  
Media centre  
Careers

Advanced search

gsk GlaxoSmithKline

Home » Responsibility » Public policy and patient advocacy » Patient group funding » **Pan European groups**

### Responsibility

- Public policy and patient advocacy
  - Our approach to external affairs
  - Public policy activity in 2008
  - Political contributions and lobbying expenditures
  - Patient advocacy
  - Patient group funding
    - UK groups
    - PAN European groups
    - National European groups
    - International groups
    - US groups
  - Q&As

### Patient group funding

During 2008, we provided financial support to the following pan European patient groups:

- AIDS Action Europe
- Alzheimer Europe
- Eurordis, European Organisation for Rare Diseases
- Europa Donna
- European AIDS Treatment Group
- European Cancer Patient Coalition
- European Cervical Cancer Association
- European Coalition of Positive People
- European Federation of Allergy and Airways Diseases Patients Associations
- European Federation of Neurological Associations
- European Headache Alliance
- European Institute of Women's Health
- European Multiple Sclerosis Platform
- European Parkinson's Disease Association
- European Patients' Forum
- Global Alliance of Mental Illness Advocacy Networks - Europe
- Genetic Interest Group
- Institute for Neuroanthocytosis
- International Diabetes Federation - Europe
- International Osteoporosis Foundation
- Pulmonary Hypertension Association - Europe

Find out more about the groups we supported in 2006 and 2007

Back to top

**In the community**  
What we do  
Find out more about our work in the community



# Working with patient groups – GSK

Address <http://www.gsk.com/responsibility/patient-groups/eu-po-epf.htm>

 GlaxoSmithKline

## Responsibility

- **Public policy and patient advocacy**
  - Our approach to external affairs
  - Public policy activity in 2008
  - Political contributions and lobbying expenditures
  - Patient advocacy
  - **Patient group funding**
    - UK groups
    - **PAN European groups**
    - National European groups
    - International groups
    - US groups
  - Q&As

- Home
- Responsibility
- Public policy and patient advocacy
- Patient group funding
- **PAN European groups**

## Patient group funding

### European Patients' Forum (EPF)

The vision of EPF is to ensure that the European patient voice is at the centre of healthcare. EPF works as a catalyst for advocating a strong European patient voice, enabling patient groups to join forces and develop alliances. They work with like-minded stakeholders and with the EU institutions.

We have supported this organisation since 2005.

#### During 2008:

- We gave an unrestricted grant of €40,000 to support their activities.
- We also gave EPF two honoraria of €500 to support the attendance of the Director General at GSK's European Health Advisory Board meetings.
- In addition we gave an educational grant of €40,000 to support EPF's annual Conference planned for December 2009.

Our support represents 13.49 per cent of their overall income.

#### During 2007:

- We gave an unrestricted grant of €40,000 to help them with their activities.
- We gave an educational grant of €36,250 to help support EPF's 2007 spring conference (second payment).
- We gave an educational grant of €50,000 to support EPF's spring conference planned for April 2008.
- We also gave EPF two honoraria of €500 to support the attendance of the Director General at GSK's European Health Advisory Board meetings.

Our support represented 25.3 per cent of their income overall.

#### In 2006:

- We provided €95,000 as an unrestricted grant to help support their activities.
- We gave an additional unrestricted grant of €36,250 to support EPF's spring conference planned for 2007.
- We also gave EPF an honorarium of €500 to support the attendance of the Director General at GSK's European Health Advisory Board meeting.

Our support represented 17 per cent of their income overall.



#### In the community

What we do

➤ Find out more about our work in the community







# Working with patient groups – GSK USA

http://us.gsk.com/docs-pdf/responsibility/gsk-grants-1q2009.pdf

is a Copy Search Select 98%

 <b>Grants &amp; Charitable Contributions to US Based Healthcare Organizations</b> 1st Quarter 2009		
Organization Name	Project Description	Amount
Acquired Immunodeficiency Syndrome Action Incorporated - Baltimore	Acquired Immunodeficiency Syndrome Action Baltimore Community Forums	\$10,000
ACVP/STP Coalition for Veterinary Pathology Fellows	Veterinary Pathology Training Program	\$63,776
ACVP/STP Coalition for Veterinary Pathology Fellows	Veterinary Pathology Training Program	\$53,949
ACVP/STP Coalition for Veterinary Pathology Fellows	Veterinary Pathology Training Program	\$63,626
Albany Medical College	10th Annual Human Immunodeficiency Virus Clinical Care Symposium	\$5,000
Alex's Lemonade Stand Foundation	Lemon Ball 2009 Platinum Sponsorship	\$10,000
Alzheimer Association	2009 Research Roundtable Membership	\$50,000
American Academy of Continuing Medical Education	American Conference for the Treatment of Human Immunodeficiency Virus	\$50,000
American Academy of Pediatrics - Georgia Chapter	Educating Physicians in Their Communities: Immunization Education	\$20,000
American Academy of Physician Assistants	37th Annual Conference Session - Interactive Case Studies in Asthma	\$6,500
American Association for Cancer Research	2009 Annual Meeting - Clinical Scholars Award	\$40,000
American Association for Cancer Research	2009 Annual Meeting - Elion Award	\$60,000
American Association for the Study of Liver Disease	New Challenges - New Solutions Campaign	\$100,000
American Association of Clinical Endocrinologists	Cardiovascular Disease Risk in Patients with Type 2 Diabetes: A Call to Action for the Endocrinologist	\$129,859
American Cancer Society - Pennsylvania Division	Coaches vs. Cancer: 11th Annual Tourney Tip-Off Breakfast & 6th Annual Basketball Gaia	\$30,000
American Chemical Society - Division of Organic Chemistry	Support 41st National Organic Chemistry Symposium	\$1,000
American College of Chest Physicians	American College of Chest Physicians - 2009 Sleep Medicine	\$15,000
American College of Neuropsychopharmacology	2009 Corporate Supporting Fee	\$50,000
American Dental Hygienists Association	Continuing Education Sessions	\$10,500
American Headache Society	Annual Scientific Meeting of the Headache Cooperative of the Pacific	\$20,000
American Headache Society	Neurology Resident Curriculum	\$25,000
American Headache Society	Online Headache Education Program	\$20,000
American Pharmacists Association	American Pharmacists Association 2009 Annual Meeting Educational Session: Migraine Management: A Head Start for Pharmacists	\$20,500

May, 2009 1



# Working with Patient groups Novartis

http://www.corporatecitizenship.novartis.com/patients/patient-partnership/patient-groups.shtml

worldwide sites | contact | help | large text version



Welcome to **Citizenship@Novartis**

Home | Managing corporate citizenship | **Patients** | Business conduct | People and communities | Environmental care | Citizenship in action



## Patients

- Value of medicines
- Access to medicines
- Drug pricing
- Patient safety

### Patient groups

- ▶ **Patient group support**
- ▶ Establishing high standards
- ▶ Understanding medical needs and the healthcare environment
- ▶ Initiatives underway

## Patient group support

Intro

Europe

US

Multinational

Novartis interacts with many patient groups. These groups play a crucial role by informing and supporting patients, as well as safeguarding the rights of patients and caregivers. Further, patient groups provide pharmaceutical companies with important advice from their own perspective.

Interacting with patient organizations enables Novartis to learn about unmet patient needs, and this information can guide us in the development of new medicines.

In all our interactions with patient groups, we are committed to working ethically and transparently while respecting their integrity. With regards to the disclosure of patient group support, Novartis is fully compliant with all legal and statutory requirements as a minimum standard in a given country. We commit to disclose the names of patient groups that have received funding or non-monetary support from Novartis as well as the purpose of this support in Europe, the US and for international groups. This list is updated annually.

[Read our position on Patient group interaction and support >](#)


Search

## CASE STUDIES



By implementing standards of business conduct beyond corporate and national boundaries, Novartis is not only improving relations with suppliers but also boosting its own performance.

[Find out how >](#)



# Working with Patient groups

## Novartis

**Patient group support**

Intro **Europe** US Multinational

Please mouse over the group's name to see the purpose of support

- Albania**
- Austria**
  - Alzheimer Angehörige Austria
  - Alzheimer Angehörige und Betreuende
  - AMA - Austrian Myeloma Association
  - Angehörige Demenz
  - ARGE Brustkrebs Österreich
  - Austrian Transplant Sports Federation (ATSF)
  - Dachverband Österreichische Autistenhilfe
  - Die Knospe Breast Cancer Group
  - Dritter Wiener Alzheimerstag für Patienten und Angehörige
  - GHZ Eisenstadt Alzheimer
  - Help 4 you company (Aktiv mit Rheuma)
  - Hilfe zur Selbsthilfe für seelische Gesundheit




# Working with Patient groups

## Lilly UK

Address [http://www.lilly.co.uk/Nitro/newTemplates/general/Content\\_IT\\_LBCT.jsp?page=1731](http://www.lilly.co.uk/Nitro/newTemplates/general/Content_IT_LBCT.jsp?page=1731)

**Lilly** Home | Search | Contact - Lilly Worldwide -

About | Conditions | Medicines | Making a Difference | Grants | News and Policy | Careers | Supplier Information



**Making a Difference** Making a Difference > Community Programmes > Relationships with patient groups

### Lilly UK and relationships with patient groups

Lilly UK is committed to partnering with patient advocacy groups for the benefit of patients and in a way that is true to the ABPI Code of Practice and Lilly's policy.

Lilly UK works with patient groups in accordance with six principles:


1. Equal partnership - both sides must be prepared to move beyond being a passive donor or recipient of money to working together on practical initiatives to promote the best interests of patients.
2. Preserve external organisations' independence - the company must not attempt to oblige external groups to conform to a particular agenda in exchange for funding.
3. Transparency - company funding and/or sponsorship of such external groups' initiatives must be made public and explicit.
4. Written agreements - there must be a written understanding between the parties establishing the type of relationship and expectations of each.
5. Diversified funding - the company must encourage external organisations to diversify their funding so the company is not the dominant source of funding. In addition, any unsolicited requests for funding from an external organisation to Lilly must go to the Lilly Grants Committee.
6. Helping to grow existing organisations - the company should avoid creating external organisations and focus instead on helping existing organisations to grow and develop. For example, to further enhance external organisations' operational capabilities, the company may offer assistance in areas of expertise such as medical, administration, management systems, and recruiting.

### Responsibility for patient group relationships

Ongoing relationships with patient groups are the responsibility of Lilly's Corporate Affairs department.

Unsolicited requests for support from patient groups are considered by the Lilly Grants Committee, details of which can be found on [www.lilly.co.uk](http://www.lilly.co.uk) in the section called 'Making a difference'.

**Click here >**  
To see how Lilly works with patient groups



# Working with Patient groups

## Lilly UK

Marketing > Millieu > Commercial Programmes > Patient Group Funding

### Descriptions of Lilly's patient group relationships

Lilly UK is committed to partnering with patient advocacy groups for the benefit of patients and in a way that is true to the ABPI Code of Practice and Lilly's policy.

Lilly UK has agreed with patient advocacy groups that it will make public the scope of our partnerships in the UK in order to increase transparency. This includes stating the amount of funding that Lilly provides.

### Cancerbackup

Lilly has provided a grant to Cancerbackup to help the organisation raise public awareness of cancer and campaign for improved access to information and better services for people with cancer.

Lilly funding in 2007 was £17,000, which represents 0.4% of Cancerbackup's overall income.

### Depression Alliance

Lilly in partnership with Boehringer Ingelheim provided a core partnership unrestricted donation to Depression Alliance, toward enabling Depression Alliance to allocate capacity toward information sharing and advising on activities to improve the health outcomes of individuals with depression. In addition, Lilly and Boehringer Ingelheim commissioned Depression Alliance to provide advice and input into the "Now We're Talking!" disease awareness campaign that aimed to raise awareness of the need for increased support for healthcare professionals in primary care, toward delivering enhanced care for people with depression.

Lilly and Boehringer Ingelheim funding to Depression Alliance in 2007 was £20,000, which represents 11.5% of its total 2007 budget.

### > Lilly Clinical Trial Registry

[www.lillytrials.com](http://www.lillytrials.com)  
Information about  
Lilly-sponsored  
clinical trials



### > Lilly Milestones



# Working with Patient groups


## Lilly US

Address [https://www.lillygrantoffice.com/grant\\_registry.jsp](https://www.lillygrantoffice.com/grant_registry.jsp)

### Lilly Grant Office

HOME GRANT GUIDELINES GRANT REQUEST PROCESS INITIATE GRANT REQUEST **LILLY GRANT REGISTRY** INTERNATIONAL REGISTRY FAQs

Contact the Lilly Grant Office by email:  
[grantinfo@lillygrantoffice.com](mailto:grantinfo@lillygrantoffice.com)



#### Lilly Grant Registry

#### Disclosure of Grants and Contributions Funded by Lilly

Lilly has for many years provided funding in the form of educational grants and charitable contributions to support medical education, patient education, and other worthy activities that we believe increase healthcare knowledge and improve patient care. As a business that exists to serve patients, we believe in being transparent and open regarding our educational and charitable giving. That is why we are making this online public disclosure of Lilly grants and charitable contributions to healthcare-related organizations in the U.S.\*

In the United States, Lilly has two sources of grants or charitable contributions that are documented on this website:

- The U.S. Affiliate Lilly Grant Office (LGO) evaluates the majority of the requests the Company receives for grants in the United States.
- The Lilly Research Laboratories (LRL) Grant Office evaluates the majority of the requests from international organizations and some requests from U.S. agencies that operate internationally.
- For programs outside the U.S. and US possessions that are specific to the originating country, Lilly local offices are tasked with reviewing the majority of educational grant and charitable contribution requests.

#### Grant Registry Report


[Click here](#) to view the grant registry report.

#### Grant Registry FAQs

[Click here](#) to view Frequently Asked Questions about the Grant Registry.

#### Download a Brochure


[Click here](#) to download the latest version of our print brochure.



# Working with Patient groups AstraZeneca

Address <http://www.astrazeneca.com/responsibility/community-support/patient-group-support?itemId=5212120&nav=yes>

AstraZeneca Websites Search

AstraZeneca 

AstraZeneca International

- Home
- About us
- Medicines
- Research
- Careers
- Responsibility**
  - ▶ Strategy and vision
  - ▶ Safety of medicines
  - ▶ Access to medicines
  - ▶ In the developing world
  - ▶ Sales & marketing practice
  - ▶ Research ethics
  - ▶ Our employees
  - ▶ **Community support**
    - ▶ In our local communities
    - ▶ **Patient group support**
    - ▶ Memberships & charters
    - ▶ Climate change
    - ▶ Sustainable production
    - ▶ Pharmaceuticals in the environment
    - ▶ Working with suppliers
    - ▶ Management & measurement
    - ▶ Code and policies
    - ▶ Reporting performance
- Partnering
- Media
- Investors

Home ▶ Responsibility ▶ Community support ▶ **Patient group support**

Staying in touch with changing needs is vital to our aim of making the most meaningful difference we can to patient health.

We talk continuously to physicians and patient groups and organisations to understand what they need and want. This includes working with, and supporting, patient groups and organisations who represent the particular demands of specific health issues, as well as discussing with healthcare professionals the broader range of disease challenges they and their patients face.

Our ongoing aim is to ensure that all of our relationships with patient groups and other healthcare organisations continue to be based on transparency, trust and a shared objective to improve the lives of patients. Our new [Global Community Support Policy](#), launched in January 2009 reinforces that commitment.

In line with the respective UK ABPI and Swedish pharmaceutical industry association (LIF) codes of practice requirement to do so, we make public all our relationships with patient groups in the UK (through our website, [AstraZeneca.co.uk](#)) and in Sweden (through LIF's external website [LIF.se](#)). In line with the requirements of the EFPIA code, we now also report which patient groups in Europe we support (see below).

During 2008, in the absence of any external requirement to do so, AstraZeneca in the US disclosed their contributions to non-profit organisations in the US, including patient groups and other healthcare organisations, and their grants in support of independent medical education. Current information is available on our [US website](#) and this will be updated on a biannual basis.

We also collect and publish information about interactions between AstraZeneca's global therapy area teams and patient groups (see below).


Beyond this, we are continuing to develop a global framework for consistent management and capture all of our support to patient groups and other healthcare organisations worldwide. Completion of this work and publication of this information, including the nature of the relationship and the associated financial commitments, was planned for 2008 but the continued re-organisation and re-structuring within the Company during the year caused some delay. However, we are now on track to start delivering this in 2009.

**PATIENT GROUP SUPPORT - EUROPE**

- ▶ Austria
- ▶ Belgium
- ▶ Bulgaria

**Introduction to AstraZeneca**

Please upgrade to the latest version of Flash to see this video

 Get ADOBE® FLASH® PLAYER

**Did you know**

**65,000**

We have over 65,000 employees (51% in Europe, 32% in the Americas and 17% Asia, Africa and Australasia).

▶ More about our people

1 | 2 | 3 | 4 | 5

**Contact us**

▶ Email enquiry form



# Working with Patient groups

## AstraZeneca

### PATIENT GROUP SUPPORT - EUROPE

#### Austria

Patient Group	Nature of Support & Purpose
HPE Österreich	Healthcare Awareness Publications and Events
Lungenunion	Healthcare Awareness Publications and Events
Pro Mente Salzburg	Provision of Education & Training

#### Belgium

Patient Group	Nature of Support & Purpose
Europa Donna Luxembourg	Provision of Education & Training
Crohn & Colitis	Unrestricted use grant
European Patients Forum (EPF)	Unrestricted use grant
Vlaamse diabetes Vereniging - Flemish Association of Diabetes	Unrestricted use grant


#### Bulgaria

Patient Group	Nature of Support & Purpose
Асоциация на Пациентите с Онкологични Заболявания - АПОЗ, София - Association of Patients with oncology diseases - Sofia	Healthcare Awareness Project Support
Българска Асоциация на Онкоболните и Сподвижници - БАОС, Варна - Bulgarian Association of oncology patients and their supporters - Varna	Healthcare Awareness Project Support
Сдружение на Жените с Онкологични Заболявания - СЖОЗ, Пазарджик - Association of Women with oncology diseases - Pazardjik	Healthcare Awareness Project Support
Асоциация на Пациентите с Онкологични Заболявания - АПОЗ, София	Provision of Education & Training





# AstraZeneca: Global Policies

Address  <http://grouppolicies.astrazeneca.net/community-support/support-to-patient-groups.asp>

## GLOBAL POLICIES

News Search Links AZone Reference

Low-dose ASA-Neelum indication and fixed dose c next

Home

Home » Community Support, Including Product Donations and Patient Group Support » Support To Patient Groups And Other Healthcare Organizations

 Printer friendly

Search

Anti-bribery and Anti-corruption

### Support to Patient Groups and other Healthcare Organisations

Bioethics

Advanced search

Communications

Community Support, Including Product Donations and Patient Group Support

Our support to [patient groups](#) and other [healthcare organisations](#) must always comply with relevant legal and regulatory requirements and applicable international and national codes, as well as our own international and national [standards](#).

Other useful links

Community Support  
Support To Patient Groups And Other Healthcare Organisations  
Product Donations

Across all of our activities, the following principles must always apply:

- > Our support, whether through financial or in-kind assistance, must always be based on transparency, trust and a shared objective to improve patient healthcare.
- > The independence of such groups and their activities must always be respected.
- > We must not request the [promotion](#) of a particular prescription-only medicine by patient groups.
- > The arrangements for [events](#) and [hospitality](#) involving patient groups will be governed by standards similar to those in place for [healthcare professionals](#).

- AZ Community Database
- ISMO Pharma Code
- Standards for Global Team Interactions with Patient Groups
- UK Community Support Policy

Data Protection and Privacy

Legal and Intellectual Property

People

Providing Information About Our Products

Quality and Regulatory Compliance

Safeguarding Company Assets and Resources

Safety Health and Environment

Where applicable, public disclosure of support for patient groups and other healthcare organisations must be done locally in accordance with the relevant external regulations, applicable codes and local Company policy commitments.

All support to patient groups and other healthcare organisations, whether or not publicly disclosed at a local level, must be documented by a written agreement and registered on the AstraZeneca Global Community Database.

Contacts

- Global Compliance
- Rhianon Rowse

Webmaster  
David Robinson

Site Owner  
Paul Woods

Site Sponsor  
Sue Katz

Content Owner: Paul Woods, updated: 05 Jan 2009

Contact: David Robinson



# Into practice - Some points for discussion?

- **What information to provide**

- Different national requirements
- Different company interpretations and positions
- Europe: meaning of
  - 'short description of of the nature of the support'*
  - '(any) financial support and/or significant indirect/non-financial support'*
- Uncertain future requirements

- **Accounting systems**

- May require significant redesigns of international processes and IS
- Systems need to cover other sectors eg HCP support

- **Large organisations**

- Easy to miss an item of support

- **Commercially sensitive? Private data**

- Is there any justification for withholding any information?
  - Eg interactions concerning development projects*



# Into practice - Some points for discussion?

- **‘Reasonable’ event venues and hospitality**
  - Can our criteria for HCP meetings be directly applied to patient group interactions?
  - Can we provide any support if a patient group chooses an exotic location for their meeting?
- **Payments for work done**
  - Groups and/or individuals
  - Fair market value
- **Written agreements**
  - Some patient groups have their own agreement templates
- **We “*shall not request, nor shall patient organisations undertake the promotion of a particular prescription-only medicine*”**
  - What does promotion mean in this context?
  - Influence on patient group activities of recent ECJ ruling on advertising definition



Dear Signatory: I'd like to provide a prize for the local diabetes support group draw. OK?

